Company intelligence / Profile preview
M4K Pharma
Toronto, Ontario, Canada
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
M4K Pharma’s lead program targets ALK2 for DIPG, focusing on a precision medicine approach with open science; the program is in pre-clinical development, with ongoing research to identify a potent, selective, and brain-penetrant ALK2 inhibitor.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeALK2 kinase inhibitor
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Charles River Laboratories (CRO)Reaction Biology Corp (CRO)Academic collaborators globally
Beyond the preview
Go deeper on M4K Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M4K Pharma.